Opendata, web and dolomites

Everfill

Improving the Quality of Life of Millions through the Revolutionary Approach in Dermal Regeneration Care

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Everfill project word cloud

Explore the words cloud of the Everfill project. It provides you a very rough idea of what is the project "Everfill" about.

revenue    deep    estimate    defects    necrosis    conducting    capital    faster    experimental    health    launch    first    normal    severe    classification    patient    bioactive    gaining    feasibility    everfill    unhealthy    wound    diet    superior    dressings    combination    care    distorts    bioengineered    savings    damaged    allogeneic    21    tissues    building    trigger    350    life    sme    regenerate    wounds    instrument    ipr    batch    half    ageing    dimensions    million    populations    reg    proof    invested    everyday    incurable    oy    revolutionize    sales    massive    uses    contains    material    curing    quality    business    clinical    regeneration    tolerated    countries    regulatory    patented    human    trials    diabetes    triggers    off    lifestyle    people    outcomes    2019    leg    global    diseases    tissue    body    amputations    revenues    commercial    thorough    extracted    sedative    ongoing    millions    spin    initial    venture    scientific    tampere    occurrence    investors    commercialization    round    gels    safe    university    healing   

Project "Everfill" data sheet

The following table provides information about the project.

Coordinator
EVERFILL OY 

Organization address
address: FREDRIKINKATU 25 A 17
city: HELSINKI
postcode: 120
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Finland [FI]
 Project website http://www.everfill.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EVERFILL OY FI (HELSINKI) coordinator 50˙000.00

Map

 Project objective

The combination of ageing populations, sedative lifestyle and unhealthy diet results in increase in such diseases as diabetes. One of the outcomes of diabetes is the occurrence of very severe and deep leg wounds. As diabetes distorts the body’s normal tissue regeneration processes, it often results in necrosis and amputations, which are still everyday practice even in developed countries. Everfill Oy is a university spin-off that has developed Everfill®, a patented allogeneic bioengineered product that will revolutionize the care of wounds. Everfill® uses extracted human bioactive growth factors that trigger the patient’s body to regenerate damaged tissues. This results in faster and more thorough healing. As Everfill® contains only human material and triggers the patient to regenerate own tissue, it is a superior product for dressings and wound gels. It is safe and well tolerated and has no side effects. Everfill® will enable curing currently incurable tissue defects and wounds, achieve massive savings in health care, and improve the quality of life for millions of people. Our estimate of its global revenue potential is over €350 million per year. So far €0.7 million were invested into the scientific research conducted at the University of Tampere and related to Everfill® product. In order to launch the product commercialization phase, we are looking for €5 million funding for 2019-21, of which half from venture capital investors within the ongoing round A and another half from the SME Instrument. This funding will be used for gaining EU and US regulatory classification for the product, building up business process proof of concept to produce the product for clinical trials, and conducting the first phase of clinical trials in EU. Initial sales revenues from experimental patient care using the first batch of product will be generated during the project. Our SME-1 feasibility study will have IPR, legal, commercial and operational feasibility dimensions.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EVERFILL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EVERFILL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

COPI (2020)

Carbon Offset Plug-in

Read More  

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More  

MHS (2019)

Metal Hydrides Hydrogen Storage

Read More